Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | YTHDC1 | Q96MU7 | 5/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137935 | 0.84 | CDK1 (0.38) | P2RX7CDK1SRCFGFR1FGFR4 | |
| SCHEMBL27635727 | 0.83 | CDK1 (0.58) | LMNATP53CDK1PDE8AADORA3 | |
| SCHEMBL4120696 | 0.80 | FGFR1 (0.45) | P2RX7LMNASRCHDAC6FGFR1 | |
| SCHEMBL1355050 | 0.78 | P2RX7 (0.48) | P2RX7LMNATP53YTHDC1ALDH1A1 | |
| SCHEMBL29601580 | 0.78 | P2RX7 (0.48) | P2RX7LMNATP53YTHDC1ALDH1A1 | |
| SCHEMBL3416142 | 0.72 | P2RX7 (0.37) | P2RX7LMNATP53CDK1YTHDC1 | |
| SCHEMBL13212062 | 0.72 | P2RX7 (0.44) | P2RX7LMNATP53CDK1YTHDC1 | |
| SCHEMBL17484493 | 0.72 | P2RX7 (0.44) | P2RX7LMNATP53CDK1YTHDC1 | |
| SCHEMBL183035 | 0.72 | CDK1 (0.68) | P2RX7LMNATP53CDK1YTHDC1 | |
| SCHEMBL19204894 | 0.72 | P2RX7 (0.44) | P2RX7LMNATP53CDK1YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586566-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071609-B2 | Unsaturated heterocyclic derivatives | ARIAD PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1940843-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007021937-A2 | UNSATURATED HETEROCYCLIC DERIVATIVES | ARIAD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156596-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | P2RX7 1296/4885LMNA 1000/4885TP53 4489/4885 |
| US-20120178716-A1 | Unsaturated Heterocyclic Derivatives | CYP2F1, CYP2J2, ALOX5 | P2RX7 1296/4885LMNA 1000/4885TP53 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.